Press Releases

Radius Announces Scientific Presentations at the 40th European Calcified Tissue Society (ECTS) Congress and at the Joint Meeting of the International Society of Endocrinology and the Endocrine Society (ICE/ENDO 2014) 5-5-2014
Radius Announces Positive Topline Data From Phase 2 Study of Abaloparatide (BA058) for Postmenopausal Osteoporosis Using Two Delivery Systems 1-9-2014
Radius Announces Key Changes to Management Team 1-9-2014
Radius Names Robert Ward President and Chief Executive Officer 12-17-2013
Radius Health Completes $43 Million Financing to Advance BA058 for the Treatment of Osteoporosis 4-25-2013
Radius Health to Present at BIO Business Forum(R) 4-18-2013
Radius Health Completes Enrollment for Phase 3 Study of Bone-Building Osteoporosis Drug 3-12-2013
Radius Health to Present at Cowen & Company 33rd Annual Health Care Conference in Boston 2-26-2013
Radius Health to Present at BIO CEO & Investor in New York 2-8-2013
Radius Provides Update on Pivotal Phase 3 Program for BA058-SC Injection 1-7-2013
Radius Completes Enrollment for Phase 2 Study of BA058-Transdermal Patch for Treatment of Postmenopausal Osteoporosis 1-3-2013
Radius, 3M drug delivery systems announce exclusive agreement for development, commercialization of transdermal delivery of BA058 for Osteoporosis 12-20-2012
Radius Health Withdraws Registration Statement 11-15-2012
Radius Health Announces Upcoming Scientific Presentations at the American Society for Bone and Mineral Research 2012 Annual Meeting 10-12-2012
Radius Initiates Phase 2 Study of BA058-Transdermal for the Treatment of Postmenopausal Osteoporosis 9-27-2012
Radius Health Announces Upcoming Scientific Presentations at ENDO 2012, the Endocrine Society's 94th Annual Meeting 6-22-2012
Radius Announces Appointment of Michael Franken as Senior Vice President and Chief Business Officer 4-20-2012
Radius Health, Inc. Files Registration Statement for Proposed Public Offering 2-7-2012
Radius Announces Topline Results of Successful Phase 1b Clinical Trial of BA058 Microneedle Patch for the Transdermal Treatment of Osteoporosis 12-21-2011
Radius Closes $21.4 Million Third and Final Equity Tranche of Previously Announced Financing 12-16-2011
Radius Transitions Company Leadership; Names Michael Wyzga President and Chief Executive Officer to Advance Phase 3 Osteoporosis Drug and Drive Corporate Strategy 12-5-2011
Radius Closes $27.65 Million Second Tranche of Previously Announced Financing 11-23-2011
Radius Announces Closing of $91 Million Financing to Advance BA058 Injection into Phase 3 Osteoporosis Study 5-24-2011
Radius, 3M Drug Delivery Systems Sign Development Agreement for Transdermal Delivery of BA058 for Treatment of Osteoporosis 5-24-2011
Radius Presents Positive Phase 2a Study Results Establishing Clinical Proof of Concept for RAD1901 in Reducing Menopausal Hot Flashes 6-19-2010
Radius’ Investigational Bone Anabolic Agent, BA058, Increased Bone Mineral Density (BMD) at Key Fracture Sites in Phase 2 Clinical Trial in Postmenopausal Osteoporosis 8-5-2009
Radius Initiates Phase 2a Clinical Trial of RAD1901 in Menopausal Hot Flashes 3-24-2009
Radius Raises Additional $15 Million, Increasing Second Private Equity Financing Round to $82.5 Million 11-20-2008
Radius Selects First Preclinical Candidate from SARM Discovery Program for the Treatment of Muscle Loss and Other Musculoskeletal Conditions 6-9-2008
Radius Completes Enrollment of Phase 2 Clinical Trial of BA058 for Osteoporosis 4-2-2008
Radius Announces Launch of RAD1901 Clinical Program for the Treatment of Hot Flashes 1-30-2008


Press Releases 2004-2007 >